Michalkiewicz M, Huffman L J, Hedge G A
Department of Physiology, West Virginia University Health Sciences Center, Morgantown 26506.
Peptides. 1991 Nov-Dec;12(6):1181-6. doi: 10.1016/0196-9781(91)90192-r.
We used three putative vasoactive intestinal peptide (VIP) antagonists: 1) [4C1-D-Phe6,Leu17]VIP, 2) [N-Ac-Tyr1,D-Phe2] GRF(1-29)-NH2, and 3) VIP(10-28) to assess the involvement of endogenous VIP in the regulation of thyroid hormone secretion and thyroid blood flow (BF). We measured thyroid BF in ketamine-pentobarbital-anesthetized rats using the microsphere technique. Increases in thyroid BF induced by VIP administration (30 pmol-1.5 nmol/100 g b.wt.) were not affected by any of the three compounds tested at doses 10-100 times higher than that of VIP. These compounds (3-15 nmol/100 g b.wt.) also failed to affect basal thyroid BF or hormone secretion. Increases in pancreatic and salivary gland BFs induced by VIP (30 pmol/100 g b.wt.) were also not affected by [4C1-D-Phe6,Leu17]VIP or [N-Ac-Tyr1,D-Phe2]GRF(1-29)-NH2 (3 nmol/100 g b.wt.). These results indicate that the three compounds tested are not effective inhibitors of VIP receptors in the thyroid vasculature and, therefore, they cannot be used in the investigation of the functional significance of endogenous VIP in the regulation of thyroid BF.
我们使用了三种假定的血管活性肠肽（VIP）拮抗剂：1）[4C1-D-苯丙氨酸6，亮氨酸17]VIP，2）[N-乙酰基-酪氨酸1，D-苯丙氨酸2]GRF（1-29）-NH2，以及3）VIP（10-28），以评估内源性VIP在甲状腺激素分泌和甲状腺血流量（BF）调节中的作用。我们使用微球技术在氯胺酮-戊巴比妥麻醉的大鼠中测量甲状腺BF。给予VIP（30 pmol-1.5 nmol/100 g体重）所诱导的甲状腺BF增加不受三种测试化合物中任何一种的影响，这些化合物的剂量比VIP高10-100倍。这些化合物（3-15 nmol/100 g体重）也未能影响基础甲状腺BF或激素分泌。VIP（30 pmol/100 g体重）所诱导的胰腺和唾液腺BF增加也不受[4C1-D-苯丙氨酸6，亮氨酸17]VIP或[N-乙酰基-酪氨酸1，D-苯丙氨酸2]GRF（1-29）-NH2（3 nmol/100 g体重）的影响。这些结果表明，所测试的三种化合物不是甲状腺血管系统中VIP受体的有效抑制剂，因此，它们不能用于研究内源性VIP在调节甲状腺BF中的功能意义。
